Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

BACKGROUND: Anti-PD-1 therapy is increasingly used in various advanced malignancies. Patients with baseline organ dysfunction are largely excluded from clinical trials. Therefore it is unclear whether anti-PD-1 therapy is safe or effective in this setting. Further, these patients are often not candi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Kanz, Bridgette A., Pollack, Megan H., Johnpulle, Romany, Puzanov, Igor, Horn, Leora, Morgans, Alicia, Sosman, Jeffrey A., Rapisuwon, Suthee, Conry, R. Martin, Eroglu, Zeynep, Johnson, Douglas B.
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5067899/
https://ncbi.nlm.nih.gov/pubmed/27777770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0166-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky